Antibody testing after the early stages of the SARS-CoV-2 pandemic has significantly increased in the proportion of first-time blood donors.
All articles by Jonathan Goodman, MPhil
Caplacizumab appears to be safe and effective among patients with acquired thrombotic thrombocytopenic purpura treated in the real-world setting.
Latest News Your top articles for MondayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses